**Supplemental Table 2.**

|  |  |  |  |
| --- | --- | --- | --- |
| Composite | Event  | Placebo (n=1097) | Bardoxolone Methyl (n=1088) |
| **Composite of ESRD, ≥30% eGFR Decline, eGFR < 15** | **Total** | **147** | **67** |
| ESRD | 31 | 38 |
| ≥ 30% eGFR decline and eGFR < 15a | 23 | 16 |
| ≥30% eGFR decline | 30 | 6 |
| eGFR <15 | 63 | 7 |
| **Composite of ≥30% eGFR Decline, eGFR < 15** | **Total** | **116** | **29** |
| ≥ 30% eGFR decline and eGFR < 15a | 15 | 10 |
| ≥30% eGFR decline | 32 | 8 |
| eGFR <15 | 69 | 11 |

a Patients experienced a confirmed ≥ 30% eGFR decline and had eGFR < 15 ml/min/1.73 m2 at the same visit